| P50 | author | Zuyi Yuan | Q90972230 |
| P2093 | author name string | Yong Wang | |
| | Yan Wang | |
| | Lei Liu | |
| | Yaling Han | |
| | Yang Zheng | |
| | Aidong Zhang | |
| | Runlin Gao | |
| | Lijun Shen | |
| | Yongjian Wu | |
| | Zhirong Wang | |
| | Guohai Su | |
| | Maria Leonsson-Zachrisson | |
| | DAYU study investigators | |
| | Hengliang Liu | |
| | Huanyi Zhang | |
| P2860 | cites work | Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. | Q50468521 |
| | CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population. | Q51693029 |
| | 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines | Q56674421 |
| | Evaluation and characterization of the effects of ticagrelor on serum and urinary uric acid in healthy volunteers | Q83097637 |
| | [The prevalence of risk factors and status of clinical practice patterns among hospitalized patients with acute coronary syndromes] | Q85922109 |
| | [Guideline on the diagnosis and therapy of ST-segment elevation myocardial infarction] | Q86320840 |
| | Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers | Q87730194 |
| | 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q22241919 |
| | ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) | Q22242892 |
| | Antiplatelet and anticoagulation therapy for acute coronary syndromes | Q26824701 |
| | Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 |
| | 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevati | Q34491521 |
| | CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population | Q34649009 |
| | Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? | Q35373698 |
| | Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial | Q35647278 |
| | Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease | Q36221940 |
| | Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist | Q37552005 |
| | International patterns of dual antiplatelet therapy duration after acute coronary syndromes | Q37617057 |
| | Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. | Q38243032 |
| | Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome | Q38380508 |
| | Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study | Q38479485 |
| | Acute coronary syndrome in the Asia-Pacific region | Q38609728 |
| | Cardiovascular diseases in China: Current status and future perspectives | Q39068770 |
| | Long-term use of ticagrelor in patients with prior myocardial infarction | Q40263764 |
| | Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack | Q40372807 |
| | Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. | Q40533249 |
| | Clopidogrel pathway | Q41829299 |
| | Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease | Q42023858 |
| | Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. | Q45954831 |
| | Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) tria | Q46068914 |
| | Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. | Q46707933 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | acute coronary syndrome | Q266018 |
| P304 | page(s) | 47-56 | |
| P577 | publication date | 2018-02-28 | |
| P1433 | published in | Cardiovascular Drugs and Therapy | Q2473050 |
| P1476 | title | Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. | |
| P478 | volume | 32 | |